Sarah Theaker

Sarah Theaker

April 2014-Present: Breast Cancer Campaign funded PhD Studentship – T cell Modulation Group, Institute of Infection and Immunity, School of Medicine, Cardiff University.

I am currently participating in a 3 year PhD project entitled ‘Vaccines & Immunotherapy for Breast Cancer’ (supervised by Prof. Andrew Sewell, Dr. Garry Dolton, and Dr. John Miles). Throughout this project I aim to generate several highly specific CD8+ T cell clones that target novel breast cancer antigens and successfully kill tumour cells. Furthermore, I aim to design effective super-agonist peptides that could potentially be used as prophylactic or therapeutic vaccines in patients.

August 2013-February 2014: Associate Scientist – Protein & Cell Sciences Group, Biopharm R&D, GlaxoSmithKline, Stevenage.

Following my industrial placement year with GSK, I was fortunate enough to continue working within Biopharm on the validation of a novel oncology target.

2009-August 2013: Master of Biological Science (First Class Honours) in Biochemistry and Microbiology - University of Sheffield.

In my third year at university, I completed a 25-week research project with BioServ UK Ltd, focusing on the production and processing of bio-molecules from mammalian cell culture. During this time I successfully produced a commercial murine monoclonal antibody (mAb) against a haemagglutinin (HA) epitope tag. Moreover, as part of my fourth MBiolSci year I completed a 12-month industrial placement within Biopharm R&D (GlaxoSmithKline, Stevenage), in which I worked on optimising therapeutic antibody expression in E. coli.